<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>allergy and immunology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>allergy and immunology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination
Authors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/allergy-and-immunology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="allergy and immunology" />
<meta property="og:description" content="Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination
Authors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/allergy-and-immunology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-11-01T10:38:40+00:00" />
<meta property="article:modified_time" content="2023-11-01T10:38:40+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="allergy and immunology"/>
<meta name="twitter:description" content="Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination
Authors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "allergy and immunology",
      "item": "https://trxiv.yorks0n.com/posts/allergy-and-immunology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "allergy and immunology",
  "name": "allergy and immunology",
  "description": "Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination\nAuthors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L.",
  "keywords": [
    
  ],
  "articleBody": " Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination\nAuthors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L.; Wolbink, G.; Keijzer, S.; Derksen, N.; van Deelen, M.; van Mierlo, G.; Kuijpers, T. W.; Eftimov, F.; Ham, M. v.; Brinke, A. t.; Rispens, T.\nScore: 237.7, Published: 2023-10-02 DOI: 10.1101/2023.09.29.23296354\nBackgroundRepeated mRNA vaccination against SARS-CoV-2 has been shown to induce class switching to IgG4, a non-inflammatory human antibody subclass linked to tolerance. Although poorly understood, prolonged antigenic stimulation and IL-4 signalling may be instrumental in IgG4 switching. We and others have previously shown that widely used immunosuppressive drugs such as methotrexate (MTX) and TNF inhibitors (TNFi) have a minor inhibitory impact on humoral SARS-CoV-2 mRNA vaccination responses. However, the impact of such immunosuppressive drugs on IgG4 switching is unknown. AimTo study the impact of widely used immunosuppressive drugs (TNFi, MTX, or the IL-4 receptor-blocking antibody dupilumab on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. MethodsAntibody responses to the receptor-binding domain (RBD) of the spike protein upon repeated SARS-CoV-2 mRNA vaccination were measured in 604 individuals including patients with immune-mediated inflammatory diseases treated with TNFi and/or MTX, or dupilumab, as well as healthy controls and untreated patients. ResultsWe observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after a third mRNA vaccination. This IgG4 skewing was absent when primary vaccination was adenoviral vector-based and was profoundly reduced in both dupilumab- and TNFi-treated patients (\u003c1%), but only moderately in patients treated with MTX (7%). ConclusionOur results imply a major role for both IL-4/IL-13 as well as TNF in IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit future mRNA vaccine strategies, humoral tolerance induction, as well as treatment of IgG4 pathologies.\n",
  "wordCount" : "346",
  "inLanguage": "en",
  "datePublished": "2023-11-01T10:38:40Z",
  "dateModified": "2023-11-01T10:38:40Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/allergy-and-immunology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      allergy and immunology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on November 1, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.29.23296354">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.29.23296354" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.29.23296354">
        <p class="paperTitle">Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.29.23296354" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.29.23296354" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Valk, A. M.; Keijser, J. B. D.; Dam, K. v.; Stalman, E.; Wieske, L.; Steenhuis, M.; Kummer, L. Y. L.; Spuls, P. I.; Bekkenk, M. W.; Musters, A. H.; Post, N. F.; Bosma, A. L.; Horvath, B.; Hijnen, D.; Schreurs, C. R. G.; van Kempen, Z.; Killestein, J.; Volkers, A. G.; Tas, S.; Boekel, L.; Wolbink, G.; Keijzer, S.; Derksen, N.; van Deelen, M.; van Mierlo, G.; Kuijpers, T. W.; Eftimov, F.; Ham, M. v.; Brinke, A. t.; Rispens, T.</p>
        <p class="info">Score: 237.7, Published: 2023-10-02 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.29.23296354' target='https://doi.org/10.1101/2023.09.29.23296354'> 10.1101/2023.09.29.23296354</a></p>
        <p class="abstract">BackgroundRepeated mRNA vaccination against SARS-CoV-2 has been shown to induce class switching to IgG4, a non-inflammatory human antibody subclass linked to tolerance. Although poorly understood, prolonged antigenic stimulation and IL-4 signalling may be instrumental in IgG4 switching. We and others have previously shown that widely used immunosuppressive drugs such as methotrexate (MTX) and TNF inhibitors (TNFi) have a minor inhibitory impact on humoral SARS-CoV-2 mRNA vaccination responses. However, the impact of such immunosuppressive drugs on IgG4 switching is unknown.

AimTo study the impact of widely used immunosuppressive drugs (TNFi, MTX, or the IL-4 receptor-blocking antibody dupilumab on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination.

MethodsAntibody responses to the receptor-binding domain (RBD) of the spike protein upon repeated SARS-CoV-2 mRNA vaccination were measured in 604 individuals including patients with immune-mediated inflammatory diseases treated with TNFi and/or MTX, or dupilumab, as well as healthy controls and untreated patients.

ResultsWe observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after a third mRNA vaccination. This IgG4 skewing was absent when primary vaccination was adenoviral vector-based and was profoundly reduced in both dupilumab- and TNFi-treated patients (&lt;1%), but only moderately in patients treated with MTX (7%).

ConclusionOur results imply a major role for both IL-4/IL-13 as well as TNF in IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit future mRNA vaccine strategies, humoral tolerance induction, as well as treatment of IgG4 pathologies.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
